HR+HER2-晚期乳腺癌内分泌治疗临床应用的研究进展

doi:10.13481/j.1671-587x.20190347

[1] HUOBER J, THÜRLIMANN B.The role of combination chemotherapy in the treatment of patients with metastatic breast cancer[J].Breast Care (Basel),2009,4(6):367-372.
[2] CARDOSO F,FALLOWFIELD L,COSTA A,et al.Locally recurrent or metastatic breast cancer:ESMO clinical practice guidelines for diagnosis, treatment and follow-up[J].Ann Oncol,2011,22(Suppl 6):vi25-vi30.
[3] WILCKEN N,HORNBUCKLE J,GHERSI D.Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer[J].Cochrane Database Syst Rev,2003(2):CD002747.
[4] CARDOSO F,COSTA A,SENKUS E,et al.3rd ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 3)[J].Ann Oncol,2017,28(12):3111.
[5] NABHOLTZ J M,BUZDAR A,POLLAK M,et al.Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group[J].J Clin Oncol,2000,18(22):3758-3767.
[6] BONNETERRE J,BUZDAR A,NABHOLTZ J M,et al.Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma[J].Cancer,2001,92(9):2247-2258.
[7] MOURIDSEN H T.Letrozole in advanced breast cancer:the PO25 trial[J].Breast Cancer Res Treat, 2007,105(Suppl 1):19-29.
[8] PARIDAENS R J,DIRIX L Y,BEEX L V,et al.Phase Ⅲ study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women:the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group[J].J Clin Oncol,2008,26(30):4883-4890.
[9] MAURI D,PAVLIDIS N,POLYZOS N P,et al.Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer:meta-analysis[J].J Natl Cancer Inst,2006,98(18):1285-1291.
[10] ROBERTSON J F,LINDEMANN J P,LLOMBART-CUSSAC A,et al.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:follow-up analysis from the randomized ‘FIRST’ study[J].Breast Cancer Res Treat,2012,136(2):503-511.
[11] ELLIS M J,LLOMBART-CUSSAC A,FELTL D,et al.Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer:overall survival analysis from the phase Ⅱ FIRST Study[J].J Clin Oncol,2015,33(32):3781-3787.
[12] JFR R,BONDARENKO IM,TRISHKINA E,et al.Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON):An international,randomised, double-blind,phase 3 trial[J].Lancet,2016,388(10063):2997-3005.
[13] YARDLEY D A,NOGUCHI S,PRITCHARD K I, et al.Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer:BOLERO-2 final progression-free survival analysis[J].Adv Ther,2013,30(10):870-884.
[14] DI LEO A,JERUSALEM G,PETRUZELKA L,et al.Results of the CONFIRM phase Ⅲ trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer[J].J Clin Oncol,2010,28(30):4594-4600.
[15] DI LEB A,JERUSALEM G,PETRUZELKA L,et al.Final overall survival:fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial[J].J Natl Cancer Inst,2014,106(1):djt337.
[16] FINN R S,CROWN J P,LANG I, et al.The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18):a randomised phase 2 study[J].Lancet Oncol,2015,16(1):25-35.
[17] FINN R S,MARTIN M,RUGO H S,et al.Palbociclib and letrozole in advanced breast cancer[J].N Engl J Med,2016,375(20):1925-1936.
[18] HORTOBAGYI G N,STEMMER S M,BURRIS H A,et al.Ribociclib as first-line therapy for HR-positive, advanced breast cancer[J].N Engl J Med,2016,375(18):1738-1748.
[19] GOETZ M P,TOI M,CAMPONE M,et al.MONARCH 3:Abemaciclib as initial therapy for advanced breast cancer[J].J Clin Oncol,2017,35(32):3638-3646.
[20] CRISTOFANILLI M,TURNER N C,BONDARENKO I,et al.Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3):final analysis of the multicentre, double-blind,phase 3 randomised controlled trial[J].Lancet Oncol,2016,17(4):425-439.
[21] SLEDGE G W,TOI M,NEVEN P,et al.MONARCH 2:Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy[J].J Clin Oncol,2017,35(25):2875-2884.
[22] SLAMON D J,NEVEN P,CHIA S,et al.Phase Ⅲ randomized study of ribociclib and fulvestrant in hormone receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:MONALEESA-3[J].J Clin Oncol,2018,36(24):2465-2472.
[23] BACHELOT T,BOURGIER C,CROPET C,et al.Randomized phase Ⅱ trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors:a GINECO study[J].J Clin Oncol,2012,30(22):2718-2724.
[24] ROYCE M,BACHELOT T,VILLANUEVA C,et al.Everolimus plus endocrine therapy for postmenopausal women with estrogen receptor-positive,human epidermal growth factor receptor 2-negative advanced breast cancer:A Clinical Trial[J].JAMA Oncol,2018,4(7):977-984.
[25] KORNBLUM N,ZHAO F M,MANOLA J,et al.Randomized phase Ⅱ trial of fulvestrant plus everolimus or placebo in postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer resistant to aromatase inhibitor therapy:Results of PrE0102[J].J Clin Oncol,2018,36(16):1556-1563.
[26] WILSON F R,VARU A,MITRA D,et al.Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer[J].Breast Cancer Res Treat,2017,166(1):167-177.
[27] KLOKE O,KLAASSEN U,OBERHOFF C,et al.Maintenance treatment with medroxyprogesterone acetate in patients with advanced breast cancer responding to chemotherapy:results of a randomized trial. Essen Breast Cancer Study Group[J].Breast Cancer Res Treat,1999,55(1):51-59.
[28] LIM S, LEE S,HAN J,et al.Prolonged clinical benefit from the maintenance hormone therapy in patients with metastatic breast cancer[J].Breast,2013,22(6):1205-1209.
[29] DUFRESNE A,PIVOT X,TOURNIGAND C,et al.Maintenance hormonal treatment improves progression free survival after a first line chemotherapy in patients with metastatic breast cancer[J].Int J Med Sci,2008,5(2):100-105.
[30] BERTELLI G,GARRONE O,BERTOLOTTI L,et al.Maintenance hormone therapy with letrozole after first-line chemotherapy for advanced breast cancer[J].Oncology,2005,68(4-6):364-370.
[31] ALBA E,RUIZ-BORREGO M,MARGELÍ M,et al.Maintenance treatment with pegylated liposomal doxorubicin versus observation following induction chemotherapy for metastatic breast cancer:GEICAM 2001-01 study[J].Breast Cancer Res Treat,2010,122(1):169-176.
[32] PARK Y H, JUNG K H,IM S A,et al.Phase Ⅲ,multicenter, randomized trial of maintenance chemotherapy versus observation in patients with metastatic breast cancer after achieving disease control with six cycles of gemcitabine plus paclitaxel as first-line chemotherapy:KCSG-BR07-02[J].J Clin Oncol,2013,31(14):1732-1739.
[33] SI W,ZHU YY,LI Y,et al.Capecitabine maintenance therapy in patients with recurrent or metastatic breast cancer[J].Braz J Med Biol Res,2013,46(12):1074-1081.
[34] DONG G L,JIA Y,WANG X R,et al.The comparison of maintenance treatment with capecitabine (CMT) and non-maintenance treatment with capecitabine (non-CMT) in patients with metastatic breast cancer[J].Int J Clin Exp Med,2015,8(5):8283-8287.
[35] SURMELI Z G,VAROL U,CAKAR B,et al.Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer[J].Oncol Lett,2015,10(4):2598-2602.
[36] 赵韬, 邵清, 张汀荣, 等. 希罗达在转移性乳腺癌维持治疗中的疗效观察[J].实用临床医药杂志,2011,15(7):88-90.
[37] CHEN X L,DU F,HONG R X,et al.Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative,metastatic breast cancer[J].Chin J Cancer,2016,35:39.
[38] LIANG X,YAN Y,WANG L N,et al.First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients[J].Oncol Lett,2015,9(2):987-993.
[39] 齐帆.晚期乳腺癌维持治疗的优化及循环肿瘤DNA在临床应用的探索性研究[D].北京:中国人民解放军军事医学科学院,2015.

Research progress in clinical application of endocrine therapy for HR+HER2-advanced breast cancer

PDF (PC)

Like

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Metrics

Comments

Recommended 0

[1]	. Research progress in anti-tumor effect and mechanism of photodynamic therapy [J]. Journal of Jilin University Medicine Edition, 2018, 44(01): 200-204.
[2]	DENG Ziliang, WANG Sen, LI Peng, XIE Kuilong, LI Shuxian, ZHOU Shixiong, HE Xiaozhou, CHEN Dong, GUO Hongsheng. Enhancement of IL-37 in chemosensitivity of cervical cancer HeLa cells to cisplatin [J]. Journal of Jilin University Medicine Edition, 2017, 43(05): 862-866.
[3]	. Progress research on mechanism of endocrine resistance in patients with estrogen receptor positive breast cancer [J]. Journal of Jilin University Medicine Edition, 2017, 43(02): 454-458.
[4]	. Advanced research on relationship between tumor microenvironment and radiosensitivity of tumor cells [J]. Journal of Jilin University Medicine Edition, 2016, 42(05): 1038-1044.
[5]	HUANG Xiaodong, LU Qian, SHEN Nan, WANG Yanchun. Inhibitory effects of Alkaline S.chinenis polysaccharides on proliferation and invasion abilities of colon cancer HT-29 cells in vitro [J]. Journal of Jilin University Medicine Edition, 2015, 41(02): 287-290.
[6]	QI Yali, ZHAO Dali, LIU Yanjun, GONG Shouliang, WANG Zhicheng. Effects of Akt combined with ionizing radiation onapoptosis, autophagy and proliferation in breast cancer MCF-7 cells [J]. Journal of Jilin University Medicine Edition, 2015, 41(01): 1-5.
[7]	LI Chang-ling,LIN Di,XING Si-ning,ZHAO Song,CHEN Hui-peng,ZHOU Fan,MA Dong-chu. Inhibitory effect of metformin on proliferation of megakaryocytic leukemia cell line Dami and its mechanism [J]. Journal of Jilin University Medicine Edition, 2014, 40(03): 534-538.
[8]	WANG Bo,GU Jun-lian,DAI Yu-xin,TONG Li-jun,MENG Ling-na,LI Yang.  Inhibitory effect of indomethacin combined with radiation on proliferation of human acute myeloid leukemia HL-60 cells [J]. Journal of Jilin University Medicine Edition, 2013, 39(2): 218-221.
[9]	ZHANG Mao,JIN Hai-guo, SU Qing-xiu\|BU Ming-wei, LI Yu-ping,LIU Gui-gang . [J]. J4, 2012, 38(4): 784-787.
[10]	LI Yan-bo,WANG Zhi-cheng\|ZHANG Yan-qiu\|DONG Li-hua,LIU Yang,LI Jin-hua. Effects of TRAIL and endostatin double-gene-radiotherapy on proliferation,cell cycle procession and apoptosis \|in human vascular endothelial \|cells [J]. J4, 2012, 38(4): 611-617.
[11]	QUAN Hai-ying\|WANG Ming-yan\|ZHANG Tong-fei\|GAO Ying\|BAI Yu\|ZHAO Xuan-yi. Mechanism of 3-methyladenine in promoting sensitivity of chemotherapeutics in oral squamous cell carcinoma in vitro [J]. J4, 2012, 38(1): 50-53.
[12]	GUO Cai-Xia, LI Yan-Bo, WANG Bin, YU Yiang, YU Yong-Bei, DUAN Jun-Chao, SUN Zhi-Wei. Enhancement of antiproliferative and proapoptotic effects of cadmium chloride when coupling with Smac over-expression in hepatocellular carcinoma cells [J]. J4, 2011, 37(4): 571-576.
[13]	. Anti-tumor effects of ^125I radioactive particles implantation on transplantated tumor model of human breast cancer cells in nude mice [J]. J4, 2011, 37(2): 275-278.
[14]	. Inhibitory \|effects \|of curcumin associatedwith CIK cells \|on proliferation of \|ovarian carcinoma cells and their mechanisms [J]. J4, 2011, 37(2): 220-225.
[15]	LI Yan-Bo, GUO Cai-Xia, GONG Peng-Sheng, LIU Yang, LIANG Shuo, WANG Hong-Fang, WANG Jian-Feng, GONG Shou-Liang. Construction and identification of double-gene co-expression vector with radiation-inducible human TRAIL and endostatin [J]. J4, 2010, 36(6): 1007-1011.